Home / News / Pearce IP Blog
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
15 DEC 2023 | KR | Approval Alert: LG Chem’s Xelenka® Biosimilar to AbbVie’s Humira® (adalimumab) Approved in Korea...
08 DEC 2023 | US | FDA Approves First Cell-Based Gene Therapies Casgevy® and Lyfgenia® to Treat Sickle Cell Disease...
01 DEC 2023 | US | Celltrion Files BLA for Interchangeable Prolia® (Denosumab) Biosimilar with the FDA The Korea...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
24 NOV 2023 | Celltrion Applies For EU Approval of CT-P42, Biosimilar to Regeneron’s Eylea® (aflibercept) Celltrion...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
16 NOV 2023 | US | Approval Alert: AZ’s Truqap® (capivasertib) plus Faslodex® FDA Approved to Treat Advanced...
On 9 August 2023, the Registrar of Trade Marks handed down a decision in favour of Nova Pharmaceuticals Australasia...
10 NOV 2023 | EU | CHMP Positive Opinion for 8mg Eylea® (Aflibercept) Bayer announced that the EMA’s Committee for...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
With over 150 rivaroxaban products approved (9 of them for Bayer), the outcome of the Sandoz challenge to the validity...
01 NOV 2023 | EU | Fresenius Kabi’s Launches First EU Tocilizumab Biosimilar Fresenius Kabi announced it has...
The Australian government has made numerous claims for damages against patentees for savings forgone when an...
27 OCT 2023 | US | Sanofi to Spin-Off Consumer Business and Focus on Biopharma by End Q4 2023 Sanofi announced that it...